Welcome to Grünenthal. This site uses cookies. Read our policy.

Accept Cookies

Bisphosphonates Case Study

Our Research into
Niche Pain Conditions

Bisphosphonates Case Study

Complex regional pain syndrome (CRPS): an orphan disease associated with chronic, extreme, debilitating pain

 

Neridronate

Neridronate is an amino-bisphosphonate with structural similarities to alendronate and pamidronate. Its use in CRPS is based on the broad effects of bisphosphonates and the multiple targets involved in the complex disease.

Please select a section above for more information

 

The Team

Our neridronate team is dedicated to the patient-centered development of this compound for the niche indication CRPS.

The team consists of several expert functions with compelling insights across a number of areas, including:

  • Pre-clinical development
  • Clinical development
  • Pharmaceutical development
  • Regulatory affairs

The team is represented by Dr Achim Kless, who leads the CRPS disease team.

Latest Updates

CGRP Antibodies in Migraine

Calcitonin gene-related peptide (CGRP)-targeted antibodies represent the first in a new class of drugs designed for the preventive treatment of migraine in adults. Following the recent FDA approval in this drug group, we review the pathophysiology of migraine and how these novel treatments can revolutionise prevention of this debilitating condition.

... Discover more

IMI-PainCare Initiative

The Innovative Medicines Initiative (IMI) PainCare initiative is a consortium composed of 40 participants from 14 countries, co-led by Grünenthal and the University of Heidelberg. The three sub-projects, PROMPT, BioPain and TRiPP, aim to revolutionise different aspects of pain research and development, and pain management with the aim of improving the care of patients suffering from acute or chronic pain.

... Discover more

Re-defining pain through patient-inspired R&D

... Discover more

Placebo Effect and Pain – Part 3

In this latest article on the placebo effect and pain, we look at the findings from a recently published trial supported by Grünenthal that shows promise for reducing the likelihood of clinical trial failure due to variations and bias in symptom reporting by participants. The background to this study and its implications are discussed.

... Discover more

Like
Share

Share this with:

These are external links and will open in a new window